Zoetis Inc (NYSE:ZTS) stock fell 3.35% (As on November 5, 11:18:37 AM UTC-4, Source: Google Finance) after the company posted mixed results for the third quarter of FY25. Net income for the third quarter of 2025 was $721 million, or $1.63 per diluted share, an increase of 6% and 9%, respectively, on a reported basis. The company continues to expand its differentiated dermatology offerings around the world with the approval of Apoquel Chewable in Chile and the labeling of Cytopoint for the treatment of allergic dermatitis in Brazil. In parasiticides, Simparica Trio received approval in Brazil and gained new label indications in various international markets, demonstrating the company’s commitment to continued lifecycle innovation to address the unmet needs of its customers
Moreover, Revenue in the U.S. segment was $1.3 billion, a decrease of 2% on a reported basis and an increase of 3% on an organic operational basis compared with the third quarter of 2024. Sales of the company’s innovative companion animal products were flat for the quarter. Growth in the company’s parasiticides portfolio, including Simparica and Revolution franchises, diagnostics and key dermatology portfolio, including Apoquel Chewable, were offset by a decline in the company’s monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela for dogs and Solensia ® for cats. Sales of livestock products declined 9% on a reported basis in the quarter, largely due to the divestiture of the medicated feed additive (MFA) product portfolio and related assets. Revenue in the International segment was $1.1 billion, a 3% increase on a reported basis and a 6% increase on an organic operational basis compared with the third quarter of 2024. Sales of the company’s innovative companion animal products grew 8% on a reported basis and 4% operationally. Portela, the first monoclonal antibody therapy with a three-month dosing interval approved for the alleviation of pain associated with OA in cats, received marketing authorization in the EU.
ZTS in the third quarter of FY25 has reported the adjusted earnings per share of $1.7, beating the analysts’ estimates for the adjusted earnings per share of $1.62, according to the Zacks Consensus Estimate. The company had reported the adjusted revenue growth of 1 percent to $2.4 billion in the third quarter of FY25, missing the analysts’ estimates for revenue by 0.35%. On an organic operational1 basis, revenue for the third quarter of 2025 increased 4% compared with the third quarter of 2024.